TUBERCULOSIS

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

J-Y Wang¹, P-R Hsueh², I-S Jan², L-N Lee², Y-S Liaw¹, P-C Yang¹, K-T Luh²

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
² Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Correspondence to:
Dr L-N Lee
Department of Laboratory Medicine, National Taiwan University Hospital, No 7, Chun Shan South Road, Taipei, 100, Taiwan; linalee{at}ccms.ntu.edu.tw

Background: A study was conducted to evaluate the effect of the empirical use of fluoroquinolones on the timing of antituberculous treatment and the outcome of patients with tuberculosis in an endemic area.

Methods: All patients with culture confirmed tuberculosis aged 14 years diagnosed between July 2002 and December 2003 were included and their medical records were reviewed.

Results: Seventy nine (14.4%) of the 548 tuberculosis patients identified received a fluoroquinolone (FQ group), 218 received a non-fluoroquinolone antibiotic (AB group), and 251 received no antibiotics before antituberculous treatment. Fifty two (65.8%) experienced clinical improvement after fluoroquinolone use. In the FQ group the median interval from the initial visit to starting antituberculous treatment was longer than in the AB group and in those who received no antibiotics (41 v 16 v 7 days), and the prognosis was worse (hazard ratio 6.88 (95% CI 1.84 to 25.72)). More patients in the FQ and AB groups were aged >65 years (53.2% and 61.0% v 31.5%), had underlying disease (53.2% and 46.8% v 34.3%), and were hypoalbuminaemic (67.2% and 64.9% v 35.1%). Of the nine mycobacterial isolates obtained after fluoroquinolone use from nine patients whose initial isolates were susceptible to ofloxacin, one (11.1%) was resistant to ofloxacin (after fluoroquinolone use for 7 days). Independent factors for a poor prognosis included empirical fluoroquinolone use, age >65, underlying disease, hypoalbuminaemia, and lack of early antituberculous treatment.

Conclusions: 14.4% of our patients with tuberculosis received a fluoroquinolone before the diagnosis. With a 34 day delay in antituberculous treatment and more frequent coexistence of underlying disease and hypoalbuminaemia, empirical fluoroquinolone treatment was associated with a poor outcome. Mycobacterium tuberculosis isolates could obtain ofloxacin resistance within 1 week.

Abbreviations: AFS, acid-fast smear; FQ, fluoroquinolone; TB, tuberculosis

Keywords: fluoroquinolone; antibiotics; tuberculosis; treatment; prognosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2006 61: 831. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• An, D. D., Hong Duyen, N. T., Lan, N. T. N., Hoa, D. V., Ha, D. T. M., Kiet, V. S., Thu, D. D. A., Van Vinh Chau, N., Dung, N. H., Sy, D. N., Farrar, J., Caws, M. (2009). Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with High-Level Fluoroquinolone Resistance in Vietnam. Antimicrob. Agents Chemother. 53: 4835-4839 [Abstract] [Full Text]  
• Shu, C-C, Wang, J-Y, Yu, C-J, Lee, L-N (2009). Mycobacterial arthritis of large joints. Ann Rheum Dis 68: 1504-1505 [Full Text]  
• Bernardo, J., Yew, W. W. (2009). How Are We Creating Fluoroquinolone-resistant Tuberculosis?. Am. J. Respir. Crit. Care Med. 180: 288-289 [Full Text]  
• Tan, C.-K., Lai, C.-C., Liao, C.-H., Chou, C.-H., Hsu, H.-L., Huang, Y.-T., Hsueh, P.-R. (2009). Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 64: 428-429 [Full Text]  
• Xu, P., Li, X., Zhao, M., Gui, X., DeRiemer, K., Gagneux, S., Mei, J., Gao, Q. (2009). Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China. Antimicrob. Agents Chemother. 53: 3170-3172 [Abstract] [Full Text]  
• (2009). Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. JAMA 301: 1014-1016 [Full Text]  
• Wang, J.-Y., Lee, L.-N., Lai, H.-C., Wang, S.-K., Jan, I-S., Yu, C.-J., Hsueh, P.-R., Yang, P.-C. (2007). Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59: 860-865 [Abstract] [Full Text]